Phio Pharmaceuticals Corp. Files 8-K with Material Agreement
Ticker: PHIO · Form: 8-K · Filed: May 17, 2024 · CIK: 1533040
| Field | Detail |
|---|---|
| Company | Phio Pharmaceuticals Corp. (PHIO) |
| Form Type | 8-K |
| Filed Date | May 17, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $621,000, $0.72 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-event, filing
TL;DR
Phio Pharma filed an 8-K on May 16, 2024, reporting a material definitive agreement and other events.
AI Summary
On May 16, 2024, Phio Pharmaceuticals Corp. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company also reported other events and filed financial statements and exhibits. This filing follows a name change from RXi Pharmaceuticals Corp. on October 19, 2011.
Why It Matters
This 8-K filing indicates a significant event for Phio Pharmaceuticals Corp., potentially involving a new partnership, acquisition, or financing, which could impact its future operations and stock value.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant positive or negative developments for the company, but the lack of specific details necessitates a medium risk assessment.
Key Players & Entities
- Phio Pharmaceuticals Corp. (company) — Registrant
- RXi Pharmaceuticals Corp. (company) — Former company name
- May 16, 2024 (date) — Date of earliest event reported
- October 19, 2011 (date) — Date of former company name change
FAQ
What is the nature of the Material Definitive Agreement entered into by Phio Pharmaceuticals Corp. on May 16, 2024?
The filing states that Phio Pharmaceuticals Corp. entered into a Material Definitive Agreement on May 16, 2024, but the specific details of this agreement are not provided in this document.
What other events are reported in this 8-K filing?
Besides the entry into a Material Definitive Agreement, the filing also reports 'Other Events' and 'Financial Statements and Exhibits'.
When was Phio Pharmaceuticals Corp. previously known by another name?
Phio Pharmaceuticals Corp. was formerly known as RXi Pharmaceuticals Corp., with the name change occurring on October 19, 2011.
What is the principal executive office address for Phio Pharmaceuticals Corp.?
The principal executive offices of Phio Pharmaceuticals Corp. are located at 11 Apex Drive, Suite 300A, PMB 2006, Marlborough, Massachusetts 01752.
What is the fiscal year end for Phio Pharmaceuticals Corp.?
The fiscal year end for Phio Pharmaceuticals Corp. is December 31 (1231).
Filing Stats: 980 words · 4 min read · ~3 pages · Grade level 10 · Accepted 2024-05-17 09:00:13
Key Financial Figures
- $0.0001 — h registered: Common Stock, par value $0.0001 per share PHIO The Nasdaq Capital M
- $621,000 — gross proceeds to the Company of up to $621,000. Triton will purchase the shares of com
- $0.72 — the Purchase Agreement at the price of $0.72 per share. The Purchase Agreement expir
Filing Documents
- phio_8k.htm (8-K) — 31KB
- phio_ex0501.htm (EX-5.1) — 9KB
- phio_ex1001.htm (EX-10.1) — 162KB
- phio_ex9901.htm (EX-99.1) — 11KB
- hoganlovellslogo.jpg (GRAPHIC) — 8KB
- image_001.jpg (GRAPHIC) — 2KB
- 0001683168-24-003598.txt ( ) — 439KB
- phio-20240516.xsd (EX-101.SCH) — 3KB
- phio-20240516_lab.xml (EX-101.LAB) — 33KB
- phio-20240516_pre.xml (EX-101.PRE) — 22KB
- phio_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On May 17, 2024, the Company issued a press release announcing the pricing of the offering. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Number Description 5.1 Opinion of Hogan Lovells US LLP. 10.1 Purchase Agreement, dated May 16, 2024, by and between Phio Pharmaceuticals Corp. and Triton Funds LP. 23.1 Consent of Hogan Lovells US LLP (included in Exhibit 5.1 ). 99.1 Press Release issued by the Company on May 17, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHIO PHARMACEUTICALS CORP. Date: May 17, 2024 By: /s/ Robert Bitterman Robert Bitterman President & Chief Executive Officer 3